Kalaris Therapeutics, Inc.
KLRS
$4.90
-$0.32-6.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.00% | 97.65% | 290.98% | 618.27% | 559.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.42% | -66.34% | 192.72% | 303.98% | 105.92% |
| Operating Income | -51.42% | 66.34% | -192.72% | -303.98% | -105.92% |
| Income Before Tax | 54.61% | 68.77% | -100.88% | -199.27% | -534.57% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 54.61% | 68.77% | -100.88% | -199.27% | -534.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.61% | 68.77% | -100.88% | -199.27% | -534.57% |
| EBIT | -51.42% | 66.34% | -192.72% | -303.98% | -105.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 96.84% | 97.74% | 85.76% | 3.09% | -2,924.93% |
| Normalized Basic EPS | 96.84% | 97.74% | 85.76% | 3.09% | -2,924.70% |
| EPS Diluted | 96.84% | 97.74% | 85.76% | 3.09% | -2,924.93% |
| Normalized Diluted EPS | 96.84% | 97.74% | 85.76% | 3.09% | -2,924.70% |
| Average Basic Shares Outstanding | 1,337.96% | 1,282.95% | 1,310.67% | 208.78% | -79.02% |
| Average Diluted Shares Outstanding | 1,337.96% | 1,282.95% | 1,310.67% | 208.78% | -79.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |